ProJenX and Unlearn Announce Partnership to Augment ALS Clinical Trial PRO-101 with Digital Twin Model (PRNewswire) - Sep 26, 2024 - "ProJenX, Inc...today announced its partnership with Unlearn to augment PRO-101, its Phase 1 clinical trial of prosetin—a brain-penetrant, MAP4 kinase (MAP4K) inhibitor—with Unlearn's advanced generative artificial intelligence (AI) technology. Unlearn, a pioneering technology company innovating machine learning to revolutionize medical research, will implement its ALS-Digital Twin Generator (ALS-DTG) to produce digital twins of PRO-101 clinical trial participants living with ALS to evaluate the clinical outcomes of ALSFRS-R, Slow Vital Capacity, and plasma neurofilament light over a 52-week open-label extension."
Licensing / partnership • Amyotrophic Lateral Sclerosis • CNS Disorders
|